NurExone Biologic Inc., operates as a pharmaceutical technology company. It is developing and commercializing the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis following spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat brain trauma injury, and other brain and neurological indications. Its technology includes ExoPTEN, for acute spinal cord injury, and glaucoma; and Exosomes, nature’s guided missiles for regeneration and healing for specific tissues. The company was founded in 2020 and is based in Toronto, Canada.